Gemma Pujol-Muncunill, Víctor Manuel Navas-López, Oren Ledder, Shlomi Cohen, Marina Lekar, Dan Turner, Kaija-Leena Kolho, Arie Levine, Nicholas M Croft, Jiri Bronsky, Dror S Shouval, Amit Assa, Rachel Harris, Fevronia Kiparissi, Marina Aloi, Nadeem Ahmad Afzal, Christos Tzivinikos, Josefa Barrio, Christoph Norden, Maria Jesús Balboa Vega, Stephan Buderus, Ana Fernández de Valderrama, Lissy de Ridder, Ruth García-Romero, Enrique Medina, César Sánchez, Marta Velasco, Saioa Vicente, David C Wilson, Sandhia Naik, Ondrej Hradsky, Lucia Cococcioni, Javier Martin-de-Carpi
Ustekinumab is an effective therapy for adult Crohn's disease (CD), but data in paediatric CD patients are scarce. The aim of the study was to describe the real-life effectiveness and safety of ustekinumab in paediatric CD. This is a multicentre review of children with Crohn's disease treated with ustekinumab. The aim of our study was to describe the effectiveness and safety of ustekinumab in paediatric real-life practice. This is a study of the Paediatric IBD (inflammatory bowel disease) Porto group of ESPGHAN...
May 3, 2024: European Journal of Pediatrics